Previous 10 | Next 10 |
Salarius Pharmaceuticals, Inc. (SLRX) Q4 2021 Earnings Conference Call March 10, 2022 17:00 ET Company Participants Jason Rando - Investor Relations David Arthur - Chief Executive Officer Mark Rosenblum - Chief Financial Officer Nadeem Mirza - Senior Vice President, Clinical Development Danie...
Salarius Pharmaceuticals press release (NASDAQ:SLRX): Q4 GAAP EPS of -$0.09 misses by $0.01. Q4 Cash and cash equivalents $29.21M For further details see: Salarius Pharmaceuticals GAAP EPS of -$0.09 misses by $0.01
Strategic acquisition of SP-3164, a targeted protein degrader in development for hematologic and solid tumors, adds to pipeline of cancer therapies Clinical development of seclidemstat is continuing with updates from two Phase 1/2 clinical trials in sarcoma and hematologic cance...
HOUSTON, March 03, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today announced that the Company will host a conference call and live audio we...
HOUSTON, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other cancers, today announced that David Arthur, CEO of Salarius Ph...
HOUSTON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other cancers, today announced that Daniela Santiesteban, Ph.D., has...
Transformative acquisition significantly expands Salarius’ oncology pipeline into the targeted degradation space with ability to go after undruggable cancer-promoting targets, a rapidly growing area of cancer drug development with multi-billion-dollar market potential. Acquis...
HOUSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc , a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that the company will present at H.C. Wainwright...
Salarius Pharmaceuticals (NASDAQ:SLRX) reached a dosing milestone in a phase 1/2 Sarcoma trial evaluating seclidemstat to treat a type of pediatric bone cancer called Ewing sarcoma and other FET-rearranged sarcomas. The trial’s Ewing sarcoma patient arm, evaluating seclidemst...
HOUSTON, Dec. 29, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, today announced an important dosing milestone in the Phase 1/2 Sarcoma c...
News, Short Squeeze, Breakout and More Instantly...
Salarius Pharmaceuticals Inc. Company Name:
SLRX Stock Symbol:
NASDAQ Market:
Salarius Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 1.7% to $112.28 on volume of 455,296,152 shares Ford Motor Company (F) fell 18.4% to $11.16 on volume of 256,384,806 shares PROSHARES TRUST (SQQQ) rose 3.4% to $9.37 on volume of 246,885,889 shares Sel...
Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) is one of today's top gainers. The company's shares have moved 57.21% on the day to $3.37. Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Secli...
A look at the top 10 most actives in the United States Predictive Oncology Inc. (POAI) rose 115.9% to $2.3099 on volume of 63,737,015 shares Selina Hospitality PLC (SLNA) fell 11.2% to $0.0406 on volume of 59,708,638 shares NVIDIA Corporation (NVDA) fell 1.4% to $112.695 on volume of 52,2...